Argenica Therapeutics (ASX:AGN) - CEO, Dr Liz Dallimore
CEO, Dr Liz Dallimore
Source: Argenica Therapeutics
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Argenica Therapeutics (AGN) is issued a notice of allowance from the US Patent and Trademark Office
  • The patent relates to the use of ARG-007 as a therapeutic compound which has been shown in animal models to reduce brain cell death following a stroke, traumatic brain injury and hypoxic ischaemic encephalopathy
  • Argenica says the notice is essential for potentially commercialising the drug in the future and anticipates being granted the US patent within months
  • Argenica is up 10.9 per cent to 74 cents at 10:58 am AEDT

Argenica Therapeutics (AGN) has been issued a notice of allowance from the US Patent and Trademark Office (USPTO) for a new patent.

The notice confirms that the patent application “Neuroprotective Peptides” is allowed for issuance as a patent.

The patent relates to the use of ARG-007 as a therapeutic compound. The neuroprotective therapeutic drug has shown efficacy in animal models to reduce brain cell death following a stroke, traumatic brain injury and hypoxic ischaemic encephalopathy.

The patent claims also covers the use of ARG-007 in Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis, Parkinson’s disease, motor neuron disease, neuropathic pain, spinal cord injury, and epilepsy.

Argenica said it anticipates the formal granting of the US patent to occur within months.

The allowance of the claims in Argenica’s US patent is considered essential to potentially commercialising ARG-007.

“We are delighted with the USPTO’s issue of the Notice of Allowance for patenting ARG-007 as a novel treatment for stroke, TBI, HIE, and other neurological conditions,” Argenica CEO, Dr Liz Dallimore, said.

“These are conditions with huge unmet medical needs in the US and represent large addressable markets that the company will look to target.

“The granting of this patent will strengthen our ability to enter into commercial negotiations with US pharmaceutical companies in the future.”

The US issue follows granted patents in Japan, China and eleven European countries.

Argenica is up 10.9 per cent to 74 cents at 10:58 am AEDT.

AGN by the numbers
More From The Market Herald
The Market Herald Video

" Askari Metals (ASX:AS2) acquires Barrow Creek Lithium project after raising $2.6m

Askari Metals (ASX:AS2) has acquired the Northern Territory Barrow Creek Lithium project after completing a $2.6…
Agrimin (ASX:AMN) - CEO, Mark Savich

" Agrimin (ASX:AMN) announces $7m cap raise

Following a trading halt earlier in the week, fertiliser development company Agrimin (ASX:AMN) has announced plans…